Comparison of efficacy of Diaskintest^®, a skin test with a recombinant tuberculosis allergen, used for 10 years and Mantoux tuberculin sensitivity test used for 110 years

The article compares results reported in national and foreign literature concerning tuberculosis detection by various in vivo (skin tests such as the Mantoux test and Diaskintest^® (a skin test with a recombinant tuberculosis allergen)) and in vitro methods (IGRA tests). A positive reaction to the Mantoux test, which has been used for over 100 years as part of mass immunization against tuberculosis, can be indicative of both earlier vaccination and of infection caused by virulent Mycobacteria tuberculosis. Given the mass scale of BCG vaccination, the positive reaction to tuberculin loses its predictive value for assessing the risk of tuberculosis. Diaskintest^®, a recombinant tuberculosis allergen, was developed in Russia in early 2000s, authorized in 2008 and has been used in the national healthcare system since 2009. This is a recombinant fusion protein ESAT6-CFP10 produced using Echerichia coli BL21(DE3)/pCFP-ESAT. Differential diagnosis between post vaccination (BCG) and bacterial allergic reactions using Diaskintest^® demonstrated high efficacy of the product - detection of tuberculosis in people with a positive reaction to the test was much higher than that of the Mantoux test. Both Diaskintest^® and IGRA tests usually do not produce false negative reactions. Therefore no additional examination of non-infected people is needed, and the preventive therapy is given only to those people who have a high risk of developing tuberculosis.

вакцина БЦЖ, проба Манту, Диаскинтест^®, тест IGRA, рекомбинантный белок ESAT6-CFP10, дифференциальная диагностика поствакцинальной и инфекционной аллергии, скрининг туберкулезной инфекции, BCG vaccine, Mantoux test, Diaskintest^®, IGRA test, recombinant protein ESAT6-CFP10, differential diagnosis between post vaccination and bacterial allergic reactions, screening for tuberculosis infection

1. Aksenova VA. Tuberculosis in children in Russia. Tuberculosis and socio-important diseases 2014; (5): 6–14 (in Russian).

2. Meisner AF, Ovsyankina ES, Stakheyeva LB. Tuberculin diagnostics in children. Latent tuberculosis infection? Problems of tuberculosis and lung diseases 2008; 85(6): 29–33 (in Russian).

3. Meisner AF, Ovsyankina ES, Stakheyeva LB. Detection of tuberculosis in Moscow adolescents. Problems of tuberculosis and lung diseases 2009; 86(1): 40–4 (in Russian).

4. Sepulveda RL, Ferrer X, Latrach C, Sorensen RU. The influence of Calmette-Guerin bacillus immunization on the booster effect of tuberculin testing in healthy young adults. Am Rev Respir Dis. 1990; 142(1): 24–8.

5. Menzies R. Tuberculin skin testing. In: Reichman LB, Hershfield ES, ed. Tuberculosis: a comprehensive international approach. New York: Marcel Dekker. Inc., 2000. P. 279–322.

6. Horowitz HW, Luciano BB, Kadel JR, Wormser GP. Tuberculin skin test conversion in hospital employees vaccinated with bacille Calmette-Guerin: recent Mycobacterium tuberculosis infection or booster effect? Am J Infect Control. 1995; 23(3): 181–7.

7. Aksenova VA, Levi DT, Zakirova HP. Modern problems of vaccine prophylaxis of tuberculosis in children. Russian Bulletin of Perinatology and Pediatrics 1999; 44(1): 3–6 (in Russian).

8. Richards NM, Nelson KE, Batt MD, Hackbarth D, Heidenreich JG. Tuberculin test conversion during repeated skin testing, associated with sensitivity to nontuberculous mycobacteria. Am Rev Respir Dis. 1979; 120(1). 59–65.

9. Bogorodskaya EM, Belilovsky EM, Puchkov KG, Senchikhina OYu, Shamuratova LF. The incidence of tuberculosis in children of an early age in the city of Moscow and the factors influencing it. Tuberculosis and socio-important diseases 2014; (5): 15–25 (in Russian).

10. Slogotskaya LV, Senchikhina OY, Nikitina GV, Bogorodskaya EM. Effectiveness of tuberculous recombinant allergen skin tests for detecting tuberculosis in children and adolescents of Moscow in 2013. Pediatric Pharmacology 2015; (1): 99–103 (in Russian).

11. Volchkova IL, Kazimirova NE, Pankratova LE. Use of diaskintest for selection of children and adolescents with latent tuberculous infection for preventive treatment. Tuberculosis and Lung Diseases 2015; (5): 64–5 (in Russian).

12. Sapozhnikova NV, Istomina EV, Starshinova AA, Panteleev AM, Zhuravlev VYu, Chernohaeva IV, et al. Impact of latent tuberculous infection among groups of the advanced risk of developing tuberculosis. Tuberculosis and Lung Diseases 2015; (7): 123 (in Russian).

13. Starshinova AA, Korneva NV, Ananiev SM, Dovgalyuk IF, Ilyina NI, Plakhtienko MV, et al. Comparison of diagnostic value of immunological testing (T-SPOT. TB and Mantoux test with 2 TU) in the diagnostics of latent tuberculosis infection in children with allergy in the medical history. Tuberculosis and Lung Diseases 2015; (7):133–4 (in Russian).

14. Comstock GW, Edwards LB, Philip RN, Winn WA. A comparison in the United States of America of two tuberculins, PPD-S and RT23. Bull World Health Organ. 1964; 31: 161–70.

15. Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold in tube assay, and T-Spot. TB test in contact investigations for tuberculosis. Chest 2009; 135(4): 1010–8.

16. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007; 146(5): 340–54.

17. Poddubnaya LV, Shilova EP, Stepchenko IM, Kononenko VG. Epidemiological factors and immunological tests when forming tuberculosis risk groups. Tuberculosis and Lung Diseases 2015; (5): 153–4 (in Russian).

18. Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, Dascher CC, et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest. 2000; 105(9): 1317–25.

19. Thye T, Browne EN, Chinbuah MA, Gyapong J, Osei I, OwusuDabo E, et al. IL10 haplotype associated with tuberculin skin test response but not with pulmonary TB. PLoS One 2009; 4(5): e5420.

20. Nyboe J. The immediate effects of BCG revaccination. Bull World Health Organ. 1969; 41(1): 63–73.